Background Psychostimulants are considered first-line pharmacotherapy for youth with
attention-deficit/hyperactivity disorder (ADHD), but questions remain regarding the …

BACKGROUND: There is increasing recognition of attention-deficit/hyperactivity disorder
(ADHD) in adults and the need to evaluate efficacy and safety of methylphenidate treatment …

Objective: The efficacy of both methylphenidate and atomoxetine has been established in
placebo-controlled trials. The present study aimed to directly compare the efficacy of …

Objectives: To identify the determinants of adherence to immediate-release (IR)
methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder …

Objective: The aim of this study was to assess changes in symptomatology of attentiondeficit/
hyperactivity disorder (ADHD) with extended-release dexmethylphenidate (d-MPHER) …

Objective: This study compared the efficacy and safety of extended-release
dexmethylphenidate (d-MPH-ER) 20 mg/day and 30 mg/day with extended-release racemic …

Methylphenidate (MPH) is the most commonly used and best-studied stimulant medication
for attention-deficit hyperactivity disorder. However, its short duration of action usually results …

Objective: To evaluate measures of sleep (exploratory endpoints) in two pivotal studies of a
multilayer bead extended-release methylphenidate (MPH-MLR) treatment of attention …

Attention deficit hyperactivity disorder (ADHD) impacts significantly on the quality of life
(QoL) of patients and their families. Choice of therapy is increasingly influenced by treatment …

Objectives: The aim of this study was to assess whether once-daily Concerta®
extendedrelease (XR) methylphenidate (MPH) is associated with:(1) better compliance;(2) …